Century Therapeutics, Inc. (IPSC) stock
IPSCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.65+0.02 (+1.23%)
Close on Nov 13, 2026Market cap $298.77MP/E –Yield –
Century Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Century Therapeutics's revenue for the twelve months ending Dec 31, 2025 was $109.16M, up 1556.8% year over year. For fiscal 2025 it was $109.16M, up 1556.8% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $109.16M | +1556.8% |
| FY2024 | Dec 31, 2024 | $6.59M | +194.8% |
| FY2023 | Dec 31, 2023 | $2.24M | -57.0% |
| FY2022 | Dec 31, 2022 | $5.20M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $0 | -100.0% |
| Q3 FY2025 | Sep 30, 2025 | $0 | -100.0% |
| Q2 FY2025 | Jun 30, 2025 | $0 | -100.0% |
| Q1 FY2025 | Mar 31, 2025 | $109.16M | +12667.7% |
| Q4 FY2024 | Dec 31, 2024 | $4.17M | +1457.1% |
| Q3 FY2024 | Sep 30, 2024 | $791.00K | +434.5% |
| Q2 FY2024 | Jun 30, 2024 | $771.00K | +678.8% |
| Q1 FY2024 | Mar 31, 2024 | $855.00K | -50.3% |
| Q4 FY2023 | Dec 31, 2023 | $268.00K | -48.6% |
| Q3 FY2023 | Sep 30, 2023 | $148.00K | -93.3% |
| Q2 FY2023 | Jun 30, 2023 | $99.00K | -92.9% |
| Q1 FY2023 | Mar 31, 2023 | $1.72M | +62.6% |
| Q4 FY2022 | Dec 31, 2022 | $521.00K | – |
| Q3 FY2022 | Sep 30, 2022 | $2.22M | – |
| Q2 FY2022 | Jun 30, 2022 | $1.40M | – |
| Q1 FY2022 | Mar 31, 2022 | $1.06M | – |
See a number that looks wrong?